Fast custom antibodies NeoClone’s exclusive license to the ABL-MYC retroviral transformation system enables accelerated production of monoclonal antibodies at potential cost savings, presenting an opportunity to target customers needing rapid turnaround and competitive pricing.

Small team agility With a lean headcount and specialized capabilities, NeoClone may be highly responsive to partnerships or contract work, appealing to mid-market biotech startups and academic labs seeking flexible collaboration, quick pilots, and personalized support.

Boutique antibody supplier Despite a small scale, NeoClone positions as a specialized provider for NeoAb and NeoClone branded antibodies, offering differentiation through speed, potentially appealing to researchers requiring niche or hard-to-find monoclonals.

Attractive funding runway Recent funding of two million dollars can support expansion into higher-volume manufacturing, additional library development, or customers requiring scalable antibody production services, signaling growth potential to prospective buyers.

Tech-enabled quality Utilizing standard web and development stacks alongside established biotech processes, NeoClone can leverage digital channels and e-commerce-friendly workflows to streamline ordering, customization, and post-sale support for research customers.